Episode 42 | NTRK 1, 2, 3 and Other Rare Mutations in NSCLC

Episode Summary

This episode provides an overview of the treatment options for rare subtypes of oncogene-driven NSCLC that are now readily identified in the MBS-reimbursed small gene panel including NTRK1, 2, 3, and other rare mutations in NSCLC.

Show Hosts

This episode’s host are:

• A/Prof Steven Kao, Medical Oncologist from Chris O’Brien Lifehouse and Clinical Associate Professor Sydney Medical School, Faculty of Medicine and Health
• Prof Wendy Cooper, senior staff specialist in Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital in Sydney, Anatomical Clinical Stream Lead for NSW Health Pathology, a Clinical Professor at the University of Sydney and a Conjoint Professor at the University of Western Sydney
• Prof Ben Solomon, head of the lung Medical Oncology Service and a Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division at Peter MacCallum Cancer Centre as well as a Founding Board member of TOGA.

Sponsor

This episode is proudly sponsored by Bayer.